C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 1/16 (2006.01) A61K 48/00 (2006.01) C12N 1/18 (2006.01)
Patent
CA 2621468
The invention generally relates to an administration strategy for the delivery at the intestinal mucosa of anti-inflammatory compounds, preferably of acid sensitive anti-inflammatory agents, such as IL10 and/or a soluble TNF receptor and/or trefoil factor via the oral route. The preferred feature according to the invention is the inoculation with a suspension of live recombinant yeast cells, preferably Saccharomyces cells which had been engineered to produce the respective proteins.
La présente invention concerne une stratégie d'administration permettant de délivrer par voie orale à la muqueuse intestinale des composés anti-inflammatoires, de préférence des agents anti-inflammatoires sensibles aux acides tels que IL10 et/ou un récepteur soluble du facteur nécrosant des tumeurs (TNF) et/ou un facteur en trèfle. Le mode de réalisation préféré de l'invention est une inoculation d'une suspension de cellules vivantes de levure recombinante, de préférence des cellules de Saccharomyces qui ont été manipulées pour produire les protéines respectives.
Iserentant Dirk
Rottiers Pieter
Vandenbroucke Klaas
Actogenix Nv
Smart & Biggar
LandOfFree
Use of recombinant yeast strain producing an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of recombinant yeast strain producing an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of recombinant yeast strain producing an... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1584725